Abstract
Acquired sideroblastic anemia, characterized by bone marrow ring sideroblasts (RS), is predominantly associated with myelodysplastic syndrome (MDS). Although somatic mutations in splicing factor 3b subunit 1 (SF3B1), which is involved in the RNA splicing machinery, are frequently found in MDS-RS, the detailed mechanism contributing to RS formation is unknown. To explore the mechanism, we established human umbilical cord blood-derived erythroid progenitor-2 (HUDEP-2) cells stably expressing SF3B1K700E. SF3B1K700E expressing cells showed higher proportion of RS than the control cells along with erythroid differentiation, indicating the direct contribution of mutant SF3B1 expression in erythroblasts to RS formation. In SF3B1K700E expressing cells, ABCB7 and ALAS2, known causative genes for congenital sideroblastic anemia, were downregulated. Additionally, mis-splicing of ABCB7 was observed in SF3B1K700E expressing cells. ABCB7-knockdown HUDEP-2 cells revealed an increased frequency of RS formation along with erythroid differentiation, demonstrating the direct molecular link between ABCB7 defects and RS formation. ALAS2 protein levels were obviously decreased in ABCB7-knockdown cells, indicating decreased ALAS2 translation owing to impaired Fe–S cluster export by ABCB7 defects. Finally, RNA-seq analysis of MDS clinical samples demonstrated decreased expression of ABCB7 by the SF3B1 mutation. Our findings contribute to the elucidation of the complex mechanisms of RS formation in MDS-RS.
Similar content being viewed by others
Introduction
Sideroblastic anemia comprises a group of congenital and acquired disorders that share the characteristic presence of bone marrow (BM) ring sideroblasts (RS), which contain excess mitochondrial deposits of iron1,2,3,4. Congenital sideroblastic anemia (CSA) is a rare condition that constitutes a diverse class of inherited disorders. Based on the pathophysiology of mitochondrial iron-heme metabolism, CSA-causative genes can be categorized into the following three subtypes: heme biosynthesis-associated genes, including 5-aminolevulinate synthase (ALAS2), solute carrier family 25 member 38 (SLC25A38), and ferrochelatase (FECH); Fe–S cluster biosynthesis-associated genes, including ATP binding cassette subfamily B member 7 (ABCB7), heat shock protein family A member 9 (HSPA9) and glutaredoxin 5 (GLRX5); and genes associated with mitochondrial protein synthesis1,2,3,4,5,6,7. The most prevalent form of CSA is X-linked sideroblastic anemia (XLSA), which is attributed to mutations in the X-linked erythroid-specific ALAS2 gene, which encodes the first rate-limiting enzyme in heme biosynthesis1,2. ALAS2 expression is mainly regulated by GATA-binding protein 1 (GATA-1), a master regulator of erythropoiesis8.
Acquired sideroblastic anemia without obvious etiologies, such as lead toxicity or copper deficiency, frequently accompanies myelodysplastic syndrome (MDS), which are bone marrow failures characterized by dysplasia and high frequencies of leukemic transformation9. Although RS can be observed irrespective of MDS subtype, MDS with more than 15% RS in BM falls into a distinct category called MDS with RS (MDS-RS), often accompanied by somatic mutations in splicing factor 3b, subunit 1 (SF3B1)10. While the prevalence of SF3B1 mutation is 20–28% in the entire MDS population11, mutation frequencies in MDS with RS (MDS-RS) are higher, with 80% and 40% for MDS-RS with single lineage dysplasia (MDS-RS-SLD) and multilineage dysplasia (MDS-RS-MLD), respectively12. Thus, the revised World Health Organization classification proposed that if a demonstrable SF3B1 gene mutation is identified, MDS-RS can be diagnosed if RS comprise as few as 5% of nucleated erythroid cells; otherwise, at least 15% RS is still required for the definite diagnosis of MDS-RS13.
SF3B1 is the largest component of the U2 small nuclear ribonucleoprotein (snRNP), which plays an important role in recognizing the branchpoint sequence (BPS), polypyrimidine tract (PyT), and 3′ splice site (3′ SS) in RNA splicing14. SF3B1 prevents aberrant splicing by strengthening the connection between the spliceosome and premature mRNA through interaction with p14 and U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1) and U2AF2 via the N-terminal HEAT domain (which consists of repeated alpha helices)15. Mutations in the HEAT domain can trigger aberrant splicing, especially the usage of alternative 3′ SS (A3SS), due to the recognition of alternative BPS caused by changes in the positional relationship between mRNA and spliceosome16. Among the various types of SF3B1 mutations that largely exist in the HEAT domain, the p.K700E mutation in exon 15 is the most frequent17.
Despite the strong association between SF3B1 mutations and RS emergence in MDS, the detailed molecular mechanisms by which SF3B1 mutations contribute to RS formation remain elusive. The expression level of ABCB7, a CSA-causative gene, is lower in MDS-RS cases than in MDS non-RS cases5,18, probably due to induced abnormal splicing of ABCB7 in SF3B1 mutated (SF3B1MUT-) MDS cases19. However, little is known regarding the detailed molecular mechanism by which SF3B1 mutation contribute to RS formation.
The hematopoietic stem cell-specific Sf3b1K700E knock-in mouse model exhibited anemia, while did not reproduce RS formation nor exhibited aberrant splicing of Abcb7, which is considered a key event in RS formation20. Although exhibition of RS formation in the SF3B1G742D-MDS-RS model cell has been reported21, the establishment of an MDS-RS model harboring SF3B1K700E is desirable because MDS with the SF3B1K700E mutation was reported to be different from MDS with other SF3B1 mutations in terms of splicing pattern and prognosis22. In addition, as the SF3B1G742D-MDS-RS model was derived from induced pluripotent stem cells (iPSCs) of an MDS-RS patient in which the additive chromosomal abnormality of t(4;12)(q31.3;q15) co-existed with the SF3B1G742D mutation21,23, the possibility of the potential contribution of co-existing chromosomal abnormalities on RS formation might not be ruled out.
Recently, we succeeded in establishing culture conditions to induce RS using XLSA models24,25. Using this methodology for human umbilical cord blood-derived erythroid progenitor-2 (HUDEP-2) cells26, we aimed to reveal the detailed molecular mechanisms of RS formation induced by SF3B1K700E.
Results
Differentiated HUDEP-2 cells stably expressing SF3B1K700E exhibited RS formation
To examine the direct link between the expression of SF3B1K700E and RS formation, we established HUDEP-2 cells stably expressing SF3B1K700E, which were subsequently induced to undergo erythroid differentiation by co-culturation with OP-9 cells (see Supplementary Fig. S1a-b online). Control vector-transduced HUDEP-2 cells and HUDEP-2 cells stably expressing SF3B1WT were used as controls. Expression of codon optimized SF3B1WT or SF3B1K700E were confirmed by RT-PCR and Sanger sequencing (see Supplementary Fig. S1c and S3 online).
Quantitative RT-PCR revealed specifical expression of codon optimized SF3B1 in HUDEP-2 cells stably expressing SF3B1WT or SF3B1K700E and global expression of internal SF3B1 in each cell line, although the expression of level of internal SF3B1 was significantly higher in HUDEP-2 cells stably expressing SF3B1K700E when compared to controls (see Supplementary Fig. S4 online). The relatively low expression level of codon optimized SF3B1K700E compared to that of codon optimized SF3B1WT might imply the survival inferiority of HUDEP-2 cells expressing SF3B1K700E at a high level. The higher level of internal SF3B1 in HUDEP-2 stably expressing SF3B1K700E than in controls could be explained as compensatory mechanism for inhibiting mis-splicing caused by abnormal SF3B1 in HUDEP-2 cells stably expressing SF3B1K700E. May–Grünwald–Giemsa staining confirmed erythroid differentiation into polychromatic and orthochromatic erythroblasts (Fig. 1a). The proportion of RS was higher in HUDEP-2 cells stably expressing SF3B1K700E than in controls (Fig. 1a, b). Electron microscopic observation of HUDEP-2 cells stably expressing SF3B1K700E revealed mitochondria containing electron-dense deposits, indicating abnormal iron accumulation (Fig. 1c).
Gene expression analysis for HUDEP-2 cells stably expressing SF3B1K700E
To detect candidate genes contributing to RS formation in HUDEP-2 cells stably expressing SF3B1K700E, we performed RNA-seq analysis based on HUDEP-2 cells stably expressing SF3B1K700E and controls. Comprehensive gene expression analysis with RNA-seq did not show apparent changes in HUDEP-2 cells stably expressing SF3B1K700E in the expression levels of CSA-causative genes, except ALAS2 (see Supplementary Table S1 online). Western blotting revealed downregulation of ALAS2 and ABCB7 in HUDEP-2 cells stably expressing SF3B1K700E (Fig. 2a). Quantitative RT-PCR demonstrated significantly decreased expression levels of ABCB7, ALAS2 and GLRX5 (Fig. 2b). These results suggested the contribution of some dysregulated CSA-causative genes to RS formation in MDS-RS.
Moreover, comprehensive gene expression analysis with RNA-seq revealed downregulation of GATA-1 target genes, including ALAS2, solute carrier family 4 member 1 (SLC4A1)27, ankyrin-1 (ANK1)28, and aminolevulinate dehydrogenase (ALAD)29 in HUDEP-2 cells stably expressing SF3B1K700E (see Supplementary Table S3 online). Decreased expression levels of mitogen-activated protein kinase 7 (MAP3K7) and GATA-1 in HUDEP-2 cells stably expressing SF3B1K700E were described by quantitative RT-PCR and western blotting (Fig. 2c, d). In contrast, quantitative RT-PCR for differentiated HUDEP-2 cells did not show dysregulation of ALAS2, MAP3K7, ABCB7, GATA-1 and GLRX5 by SF3B1K700E expression (see Supplementary Fig. S5 online). Combined with the suggested role of MAP3K7 to phosphorylate p38MAPK associated with regulating GATA-1 function30,31, SF3B1K700E expression could result in compromised GATA-1 protein expression presumably mediated by downregulation of MAP3K7.
Alternative splicing analysis for HUDEP-2 cells stably expressing SF3B1K700E
We subsequently explored the contribution of aberrant splicing induced by SF3B1K700E to the differential gene expression. Read-coverage visualization with Integrative Genomics Viewer (IGV)32 revealed an increased number of reads mapped to intron 8 of ABCB7 and intron 4 of MAP3K7 in HUDEP-2 cells stably expressing SF3B1K700E after cycloheximide (CHX) treatment (Fig. 3). These results indicated the existence of SF3B1K700E-induced A3SS events as previously reported19,33, leading to the production of splice variants targeted by nonsense-mediated decay (NMD).
Moreover, we performed comprehensive alternative splicing (AS) analysis using Mixture of Isoforms (MISO)34. MISO analysis did not detect significant differences in the number of significant AS events between HUDEP-2 cells stably expressing SF3B1WT and SF3B1K700E when compared with control vector-transduced HUDEP-2 cells (see Supplementary Fig. S12a, Tables S3-4 online). Significant AS events in HUDEP-2 cells stably expressing SF3B1K700E were not detected in ALAS2 and GLRX5, suggesting that these genes would not be downregulated through aberrant splicing induced by SF3B1K700E (see Supplementary Tables S4 online). Although the number of A3SS events detected in HUDEP-2 cells stably expressing SF3B1WT or SF3B1K700E was equivalent, most of the events did not overlap. HUDEP-2 cells stably expressing SF3B1K700E exhibited the significant A3SS event in ribonuclease/angiogenin inhibitor 1 (RNH1) (see Supplementary Fig. S12b online)33. Although aberrantly spliced isoforms were detected even in control vector-transduced HUDEP-2 cells by RT-PCR, the sashimi plot described by MISO revealed a significant increase in A3SS usage between exons 2 and 3 of RNH1 in HUDEP-2 cells stably expressing SF3B1K700E (see Supplementary Fig. S13a-b online). Sanger sequencing of RT-PCR products revealed that A3SS caused the addition of 68 bases within the 5′ untranslated region (UTR) of RNH1 (see Supplementary Fig. S13c online). However, we could not detect any difference in the expression level of RNH1 either at mRNA or at protein level between HUDEP-2 cells stably expressing SF3B1K700E and controls (see Supplementary Fig. S13d-e online).
Thus, we demonstrated that ABCB7 could be mainly downregulated via increased A3SS usage between exons 8 and 9 induced by SF3B1K700E. Moreover, downregulation of ALAS2 at the mRNA level was suggested to be associated with decreased GATA-1 function, probably caused by downregulation of MAP3K7 because of increased A3SS usage between exons 4 and 5.
Confirmation of mis-splicing–mediated downregulation of ABCB7 and MAP3K7 in K562 cells
Although downregulation of MAP3K7 and ABCB7 possibly caused by mis-splicing was detected in HUDEP-2 cells stably expressing SF3B1K700E, the incidence of A3SS events in MAP3K7 and ABCB7 was so low that the detection of A3SS events required NMD inhibition with CHX. To reinforce the evidence for mis-splicing–mediated downregulation of ABCB7 and MAP3K7 induced by SF3B1K700E, K562 cells overexpressing SF3B1K700E or SF3B1WT were generated by electroporation (see Supplementary Fig. S16 online), as confirmed using western blotting (Fig. 4a). Repeated electroporation resulted in stronger expression of SF3B1 in K562 cells expressing SF3B1WT or SF3B1K700E than in HUDEP-2 cells stably expressing SF3B1WT or SF3B1K700E. Similar to the experiment with HUDEP-2 cells (Fig. 2), quantitative RT-PCR and western blotting confirmed significantly decreased expression levels of ABCB7 and MAP3K7 both at mRNA and protein levels in K562 cells expressing SF3B1K700E compared to those in control vector-transduced K562 cells or K562 cells expressing SF3B1WT (Fig. 4a, b). The number of significant AS events detected by MISO analysis was higher in K562 cells expressing SF3B1K700E than in those expressing SF3B1WT when compared with control vector-transduced K562 cells (Fig. 4c). Lists of significant AS events can be found in Supplementary Table S5-6. Read-coverage visualization with IGV detected A3SS events between exons 4 and 5 of MAP3K7 and between exons 8 and 9 of ABCB7 in K562 cells expressing SF3B1K700E even without CHX treatment (Fig. 4d, e).
ABCB7-knockdown in HUDEP-2 cells lead to RS formation
Although ABCB7 is known to be one of the genes responsible for CSA1, the direct contribution of ABCB7 defects to RS formation has not been demonstrated. Thus, we conducted shRNA–mediated ABCB7-knockdown in HUDEP-2 cells, which were subsequently induced to undergo erythroid differentiation (see Supplementary Fig. S22 online). ABCB7-knockdown was confirmed both at mRNA and protein levels in undifferentiated HUDEP-2 cells, especially using shRNA clone 5 (Fig. 5a, b). Decreased expression level of ABCB7 in differentiated ABCB7-knockdown HUDEP-2 was confirmed by quantitative RT-PCR, unless western blotting could not be performed (Fig. 5a). Although there was no significant change in ALAS2 mRNA expression levels (Fig. 5c), ALAS2 protein levels were noticeably decreased by ABCB7-knockdown, indicating decreased ALAS2 translation (Fig. 5b). The progression of erythroid differentiation was also morphologically confirmed by May–Grünwald–Giemsa staining (Fig. 5d, upper panel). Prussian blue staining revealed an increased frequency of RS formation in ABCB7-knockdown HUDEP-2 cells compared with that in control shRNA-transduced HUDEP-2 cells (Fig. 5d, lower panel). Expression profiling analysis revealed that 39 and 20 genes were commonly upregulated and downregulated by more than 1.5-fold, respectively, in ABCB7-knockdown HUDEP-2 cells compared with control cells (see Supplementary Table S7 online). Gene ontology (GO) enrichment analysis by Metascape revealed significant enrichment of genes involved in iron metabolism and apoptosis among the commonly upregulated and downregulated genes, respectively (Fig. 6).
Collectively, we demonstrated a direct link between ABCB7 defects and RS formation, which might be associated with decreased ALAS2 translation.
Analysis of gene expression and AS using clinical samples
To confirm the contribution of downregulation of ABCB7 and MAP3K7 to RS formation in SF3B1MUT-MDS, we analyzed the RNA-seq data of clinical samples derived from MDS patients diagnosed at Tohoku University Hospital. Our cohort included eight SF3B1MUT-patients (two MDS-SLD, five MDS-RS-SLD, and one MDS-EB1) and three SF3B1WT-MDS patients (one MDS-RS-SLD, one MDS-RS-MLD, and one MDS-MLD) (see Supplementary Table S8 and Fig. S25a online). As shown in Fig. 7a, the expression levels of MAP3K7 and ABCB7 were lower in SF3B1MUT-MDS patients than in SF3B1WT-MDS patients, although not significantly lower for ABCB7. On the other hand, there was no difference in the expression levels of ABCB7 and MAP3K7 between MDS-RS and non MDS-RS patients (see Supplementary Fig. S26 online), indicating a greater contribution of SF3B1 mutation status, rather than RS existence, to the regulation of ABCB7 and MAP3K7 expression. RNA-seq read-coverage of ABCB7 and MAP3K7 visualized by IGV revealed previously reported AS events in some SF3B1MUT-MDS patients (Fig. 7b, c), although the incidence of A3SS between exons 8 and 9 of ABCB7 seemed very low. AS events in ABCB7 and MAP3K7 accompanied with lower expression levels of ABCB7 and MAP3K7 in SF3B1MUT-MDS patients indicate downregulation of ABCB7 and MAP3K7 due to degradation of mis-spliced transcripts by NMD. Additionally, the A3SS event between exons 2 and 3 of RNH1 detected in HUDEP-2 cells expressing SF3B1K700E was confirmed in both SF3B1WT- and SF3B1MUT-MDS patients, whereas the PSI of this event was relatively high in SF3B1MUT-MDS patients (See Supplementary Fig. S27 online).
Lastly, we analyzed RNA-seq dataset GSE114922 obtained from GEO RNA-seq Experiments Interactive Navigator (GREIN)35 for validating downregulation of ABCB7 and MAP3K7 in a large MDS cohort. GSE114922 contains RNA-seq data of BM CD34 positive cells derived from 54 SF3B1WT- and 28 SF3B1MUT-MDS patients36. Similar to our findings (Fig. 7), the expression levels of ABCB7 and MAP3K7 were significantly lower in SF3B1MUT-MDS patients than in SF3B1WT-MDS patients, which was also confirmed for the cohort excluding CMML (Chronic myelomonocytic leukemia) and RAEB (Refractory anemia with excess blasts) (see Supplementary Fig. S28 online). Furthermore, we aimed to find the unique role of SF3B1K700E as compared with SF3B1non-K700E. The expression levels of ABCB7 and MAP3K7 were compared among SF3B1WT-, SF3B1K700E-, and SF3B1non-K700E-MDS patients in both whole cohort and subgroups (Refractory anemia [RA] and RA with ring sideroblasts [RARS]) (see Supplementary Fig. S29–30 online). However, we could not identify any differential impact on the expression levels of these genes between SF3B1K700E- and SF3B1non-K700E-MDS patients. Then, we performed differentially expressed genes (DEGs) analysis with the web tool, iDEP37, for overviewing the expression profile of SF3B1WT-, SF3B1K700E- and SF3B1non-K700E-MDS patients. When compared to SF3B1WT-MDS patients, the number of DEGs identified in SF3B1K700E- and SF3B1non-K700E MDS was 1130 (324 genes were upregulated and 806 genes were downregulated) and 27 (2 genes were upregulated and 25 genes were downregulated), respectively (see Supplementary Fig. S31 online). Gene ontology (GO) enrichment analysis by Metascape38 revealed significant enrichment of the genes involved in oxygen transport and erythroid differentiation among the upregulated genes and those involved in the productivities or responsivities of cytokines among the downregulated genes in SF3B1K700E-MDS patients (see Supplementary Fig. S32 online).
These data imply that SF3B1K700E may exert more comprehensive impact on gene expression than SF3B1non-K700E.
Discussion
In this study, we successfully established HUDEP-2 cells expressing SF3B1K700E as an MDS-RS model (Fig. 1). This model exhibited downregulation of ABCB7, ALAS2, and GLRX5 (Fig. 2), all of which are known CSA-causative genes, indicating a cross-link between acquired and congenital SA.
ABCB7, located at Xp13.3, encodes a mitochondrial transporter of the Fe–S cluster and is responsible for XLSA with ataxia (XLSA/A)1. The mis-splicing–associated downregulation of ABCB7 detected in our MDS-RS model (Figs. 2a, b, 3a) is closely associated with MDS-RS5,18. As Abcb7-knockout mice do not survive39, RS formation by ABCB7 defects in erythroid cells has never been reproduced. Here, we firstly established ABCB7-deficient RS model by ABCB7-knockdown in HUDEP-2 cells (Fig. 5). This model showed decreased expression levels of ALAS2 at the protein level, but not at the mRNA level (Fig. 5b, c), indicating impaired ALAS2 translation by ABCB7-knockdown. ALAS2 translation is inhibited when iron regulatory protein 1 (IRP1) binds iron-responsive element (IRE) located in the 5′ UTR of ALAS2 mRNA, but is promoted when IRP1 combined with Fe–S cluster is converted to aconitase lacking the ability to bind IRE40; hence, we speculated that a decrease in cytosolic Fe–S cluster owing to downregulation of ABCB7 could contribute to RS formation by inhibiting ALAS2 translation via IRP1 activation. Further analyses are required to assess changes in aconitase activity and IRP/IRE interactions.
The molecular link between ALAS2 defects and RS formation has already been previously demonstrated24,25. Comprehensive AS analysis for HUDEP-2 cells stably expressing SF3B1K700E did not detect any AS events in ALAS2 (see Supplementary Table S4 online), indicating unlikeliness of mis-splicing–mediated downregulation of ALAS2. However, we observed downregulation of GATA-1 target genes, such as ALAS28, SLC4A126, ANK127, and ALAD29, and confirmed decreased GATA-1 protein levels (Fig. 2c). Thus, we focused on MAP3K7 as the cause of GATA-1 dysregulation in our MDS-RS model, because MAP3K7, which is activated by TGF-β, is known to phosphorylate p38MAPK, regulating GATA-1 function both by phosphorylating GATA-1 and by promoting ubiquitination and proteasomal degradation of GATA-1 via MAPKAKP2/HSP2730,31. Our MDS-RS model exhibited mis-splicing–associated downregulation of MAP3K7 (Figs. 2c, d, 3b), which was confirmed in K562 cells overexpressing SF3B1K700E (Fig. 4a, b and e) and SF3B1MUT-MDS patients (Fig. 7a and c). Downregulation of MAP3K7 mediated by mis-splicing has been reported to decrease the expression level of GATA-1 in SF3B1K700E-mutated K562 cells33. Additionally, our MDS-RS model showed increased PSI of the A3SS event within 5′ UTR of RNH1 (see Supplementary Fig. S13 online), which was also confirmed in SF3B1MUT-MDS patients (see Supplementary Fig. S27 online). RNH1 could be broadly detected in various human tissues including enucleated erythroid cells lacking RNase41. RNH1 has been reported not only as the indispensable factor for survival and development of mice due to its protective role of global RNA from RNase but also as the translational regulator for the specific genes including GATA-142,43. We hypothesized that impaired RNH1 translation associated with increased A3SS usage within 5′ UTR induced by mutant SF3B1 might contribute to the downregulation of ALAS2 at the transcription level by enhancing impaired GATA-1 translation in SF3B1MUT-MDS. Although we failed to demonstrate decreased RNH1 translation followed by impaired GATA-1 translation in HUDEP-2 stably expressing SF3B1K700E, this could be confirmed by a novel approach like polysome profiling or western blotting for each fraction of the cells. Taken together, we speculate that ALAS2 downregulation mediated by GATA-1 dysfunction may play a role in RS formation induced by SF3B1K700E expression.
Our MDS-RS model exhibited GLRX5 downregulation (Fig. 2b). Comprehensive AS analysis did not indicate mis-splicing–mediated downregulation of GLRX5 (see Supplementary Table S4 online). Although the mechanism by which downregulation of GLRX5 was induced by SF3B1K700E is unknown, it might be mediated by the downregulation of ABCB7 because ABCB7-knockdown downregulates GLRX544. The role of GLRX5 as a supplier of Fe–S cluster to IRP145 suggests that downregulation of GLRX5 could also inhibit ALAS2 translation via IRP1 activation, such as downregulation of ABCB7.
The inner mitochondrial membrane protein TMEM14C which functions in the final steps of heme synthesis as the transporter of protoporphyrinogen IX into mitochondrial matrix is highly expressed in the erythroid cells at the terminal differentiation steps46. TMEM14C expression is not under the control of IRP-IRE system46, while transcriptionally regulated by GATA-18. According to iPSC-derived SF3B1G742D-MDS-RS model, coordinated mis-splicing TMEM14C and ABCB7 contributed to RS formation21. In our models, increased frequency of the A3SS event was observed in K562 overexpressing SF3B1K700E and some SF3B1MUT-MDS patients, but not in HUDEP-2 stably expressing SF3B1K700E (see Supplementary Fig. S33–34 online). We speculated that lower expression level of SF3B1K700E compared to endogenous SF3B1 (see Supplementary Fig. S4 online) might make it difficult to detect obvious TMEM14C mis-splicing. Further analysis based on more physiological model, such as CRISPR/Cas9-mediated SF3B1 mutation in HUDEP-2 cells, would be preferred to demonstrate the detailed mechanism of RS formation by SF3B1 mutation.
In conclusion, our findings have delineated a complex mechanism for RS formation, including dysregulation of ABCB7, ALAS2, GATA-1, and MAP3K7 expression (Fig. 8). Additionally, according to the observations on ABCB7-knockdown HUDEP-2 cells, downregulation of ABCB7 could impair ALAS2 translation presumably through via IRP1 activation. These results imply a complicated mechanism for RS formation in SF3B1MUT-MDS. Further characterization of the established MDS-RS model will aid in clarifying its molecular etiology and establishing novel therapeutic strategies.
Methods
Ethical statement
Informed consent was obtained from all patients. The protocol of this study was approved by the Institutional Review Board of Tohoku University Graduate School of Medicine and was based on the ethical principles for medical research involving human subjects of the Helsinki Declaration.
Cell culture
The culture protocol for human erythroleukemia cell line K562 cells (ATCC CCL-243™, Manassas, VA), human embryonic kidney 293 T (HEK293T) cells, and HEK293T derived packaging cell line Plat-GP cells has been described previously26,47.
HUDEP-2 cells26 were maintained in StemSpan serum-free expansion medium (STEMCELL Technologies, Vancouver, BC, Canada), supplemented with 50 ng/mL stem cell factor (SCF; PEPROTECH, Rocky Hill, NJ), 3 IU/mL erythropoietin (EPO; Kyowa Hakko Kirin, Tokyo, Japan), 1 μg/mL doxycycline (DOX; Sigma-Aldrich, St. Louis, MO), and 1 μM dexamethasone (DEX; Sigma-Aldrich). The mouse mesenchymal stromal cell line OP9 cells (ATCC) was maintained in α-minimum essential medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 20% (v/v) fetal bovine serum (FBS; Biological Industries USA, Cromwell, CT) and 1% (v/v) penicillin/streptomycin (Sigma-Aldrich). To induce erythroid differentiation, HUDEP-2 cells were seeded onto OP9 cells for 6–7 days, as previously described25.
Codon-optimized SF3B1WT or SF3B1K700E overexpression
As human SF3B1 sequences are toxic to Escherichia coli48, we used codon-optimized SF3B1WT and SF3B1K700E expression vectors (Addgene Plasmid #82576 and #82577, respectively)49, encoded in pcDNA (Invitrogen, Carlsbad, CA). Each coding sequence was cloned into the retroviral vector pBABE-puro (Addgene Plasmid #1764)50.
For transient overexpression of SF3B1WT or SF3B1K700E, each pcDNA-based expression vector (10 μg) was transfected into K562 cells using the Amaxa Cell Line Nucleofector II (Lonza, Cologne, Germany) with the program T-01627,47. For retroviral overexpression of SF3B1WT or SF3B1K700E, the pBABE-puro-based expression vector and VSV-G (Addgene plasmid #12259) were co-transfected into Plat-GP packaging cell lines (Cell Biolabs, San Diego, CA) using FuGene HD (Promega, Madison, WI). Seventy-two hours after transfection, viral supernatant was used for infection. After spin infection of HUDEP-2 cells at 1300 × g for 2 h, 1 μg/mL puromycin (Sigma-Aldrich) was added to the medium to select the transduced cells.
Primers used for amplification or detection of codon-optimized SF3B1WT or SF3B1K700E expression are shown online in Supplementary Table S9.
Detection of SF3B1 mutation
Genomic DNA was extracted from whole BM lysates of MDS patients or cell lysates of SF3B1 mutant cell lines using a DNeasy Blood & Tissue kit (Qiagen N.V., Hulsterweg, Netherlands). Mutations within SF3B1 exons 14 to 16, where most SF3B1 mutations exist, were screened using high-resolution melting analysis as previously reported51, followed by confirmation of the mutations with Sanger sequences when screening tests were positive. The primer sequences used for Sanger sequencing are listed online in Supplementary Table S9.
shRNA–mediated ABCB7-knockdown in HUDEP-2 cells
Lentiviral-based knockdown of the human ABCB7 gene was conducted with pGIPZ lentiviral shRNAmir (Clone ID: V3LHS_406787) (Open Biosystems, Huntsville, USA), as described previously47. The lentiviral vectors VSV-G and psPAX2 (Addgene plasmid #12260) were co-transfected into HEK293T cells; 72 h after transfection, the viral supernatant was used for infection, as in the retroviral overexpression protocol.
Quantitative RT-PCR
Quantitative RT-PCR were conducted as described previously27. Primers used for quantitative RT-PCR are listed online in Supplementary Table S9.
Expression profiling analysis
For RNA-seq analysis, total RNA was extracted from whole BM cells of MDS patients (see Supplementary Table S8 online) or cell pellets when analyzing cell lines using TRIzol reagent. For library preparation, the SMARTer Ultra Low RNA Kit (Illumina, San Diego, CA) and Illumina TruSeq stranded mRNA Library kit were used for clinical samples and the NEBNext Ultra II RNA Library Prep Kit for Illumina was used for cell lines. Libraries were sequenced on an Illumina NovaSeq6000 (Otogenetics, Norcross, GA, USA). Sequence data were mapped to the human reference genome, hg19/GRCh37, using HISAT2 (version 2.2.1) (http://daehwankimlab.github.io/hisat2/)52. Normalized expression level of each gene was calculated as transcripts per million using StringTie (version 2.1.7) (https://ccb.jhu.edu/software/stringtie/)53.
Microarray analysis was conducted using a Human Oligo chip 25 k (Toray, Tokyo, Japan), and subsequent GO enrichment analyses were performed using Metascape38. For global normalization, the background value was subtracted and subsequently adjusted to an average signal value of 25, and genes with > 100 were analyzed.
DEGs analysis for GSE114922 dataset was performed with web tool, iDEP.951 (http://bioinformatics.sdstate.edu/idep/)37 based on normalized count data obtained from GREIN. We selected DESeq2 method for DEGs identification setting false discovery rate cut off at 0.05 and a minimum fold change at 1.5.
Alternative splicing analysis
The AS events of each sample were analyzed using MISO software (version 0.5.4) (https://miso.readthedocs.io/en/fastmiso/) with exon-centric analysis separately for A3SS, alternative 5′ splice site (A5SS), mutually exclusive exons (MXE), retained introns (RI) and skipping exons (SE)34. Human genome (hg19) alternative events v2.0 (https://miso.readthedocs.io/en/fastmiso/annotation.html), was used for MISO annotation. Among AS events extracted by the “compare miso” command, we considered the AS events passing all filtering criteria as significant, which in our study is as follows: (a) at least one inclusion read and one exclusion read, such that (b) the sum of inclusion and exclusion reads is at least 10, (c) the Δ PSI (percent spliced in) is ≥ 0.20, and (d) the Bayes factor is at least 10. AS events were expressed with visualized read-coverage using IGV32 or the Sashimi plot command in IGV or MISO.
Cycloheximide treatment
As splice variant isoforms containing premature stop codons (PTCs) are targeted by NMD, which decreases the number of splice variant isoforms54, the less expressed splice variant isoforms are sometimes difficult to detect. Cycloheximide (Nacalai Tesque, Inc., Japan), an NMD inhibitor, was added to HUDEP-2 cells stably expressing SF3B1WT or SF3B1K700E at a final concentration of 100 ug/mL19.
Production of cytospin slides and staining
Cytospin preparation and staining with May–Grünwald–Giemsa stain (Merck KgaA, Darmstadt, Germany) or Prussian blue (ScyTek Laboratories, Inc., West Logan, UT) were performed as described previously25. RS was defined as erythroblasts with ≥ five iron granules surrounding at least one-third of the nuclear lesion55.
Electron microscopy
An electron microscope (H-7600; Hitachi) was used. The protocols for sample preparation have been described by Saito et al.25.
Western blot analysis
Western blotting was conducted using whole-cell extracts, as described previously25. The expression level was quantified by densitometry with ImageJ56, relative to the expression level of the control. The primary antibodies used were as follows: α-Tubulin (CP06; EMD Millipore, Billerica, MA, USA), SF3B1 (27684-1-AP; Proteintech, Rosemont, USA), ALAS2 (ab184964; Abcam, Cambridge, UK), ABCB7 (LS-B13035, Lifespan BioSciences, Seattle, WA, USA), MAP3K7 (#5206, Cell Signaling Technology, Danvers, MA, USA), RNH1 (10345-1-AP, Proteintech, USA), FLAG (#14793, Cell Signaling Technology) and GATA-1 (#3535, Cell Signaling Technology).
Statistical analysis
All statistical analyses were performed using GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA, http://www.graphpad.com/). Nonparametric analysis was adopted because of the small sample size. The Mann–Whitney U test was used for comparing two groups and the Kruskal–Wallis test for comparing equal or more than three groups, followed by Dunn’s test. Statistical significance was set at p < 0.05.
Data availability
Raw sequence data obtained by RNA-seq discussed in this study are available in the DDBJ Sequenced Read Archive (DRA) under accession numbers DRX315782 to DRX315799 and DRX337379 to DRX 337383. We obtained RNA-seq dataset GSE114922 deposited by Pellagatti et al.36 from GREIN (http://www.ilincs.org/apps/grein/)34. Microarray data of ABCB7-knockdown HUDEP-2 cells can be found in Supplementary Table S7 available with the online version of this article. The Lists of significant AS events detected in HUDEP-2 cells stably expressing SF3B1WT or SF3B1K700E when compared with control vector-transduced HUDEP-2 cells and those detected in K562 cells stably expressing SF3B1WT or SF3B1K700E when compared with control vector-transduced K562 cells can be found in Supplementary Table S3-6 available with the online version of this article.
References
Fujiwara, T. & Harigae, H. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic. Biol. Med. 133, 179–185. https://doi.org/10.1016/j.freeradbiomed.2018.08.008 (2019).
Harigae, H. & Furuyama, K. Hereditary sideroblastic anemia: Pathophysiology and gene mutations. Int. J. Hematol. 92, 425–431. https://doi.org/10.1007/s12185-010-0688-4 (2010).
Ducamp, S. & Fleming, M. D. The molecular genetics of sideroblastic anemia. Blood 133, 59–69. https://doi.org/10.1182/blood-2018-08-815951 (2019).
Camaschella, C. Hereditary sideroblastic anemias: Pathophysiology, diagnosis, and treatment. Semin. Hematol. 46, 371–377. https://doi.org/10.1053/j.seminhematol.2009.07.001 (2009).
Nikpour, M. et al. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. Br. J. Haematol. 149, 844–854. https://doi.org/10.1111/j.1365-2141.2010.08174.x (2010).
Pellagatti, A. et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: Involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 108, 337–345. https://doi.org/10.1182/blood-2005-12-4769 (2006).
Miura, S. et al. EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells. Blood Cells Mol. Dis. 78, 1–8. https://doi.org/10.1016/j.bcmd.2019.04.014 (2019).
Fujiwara, T. et al. Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. Mol. Cell 36, 667–681. https://doi.org/10.1016/j.molcel.2009.11.001 (2009).
Nimer, S. D. Myelodysplastic syndromes. Blood 111, 4841–4851. https://doi.org/10.1182/blood-2007-08-078139 (2008).
Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627. https://doi.org/10.1182/blood-2013-08-518886 (2013).
Visconte, V. et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 26, 542–545. https://doi.org/10.1038/leu.2011.232 (2012).
Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384–1395. https://doi.org/10.1056/NEJMoa1103283 (2011).
Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405. https://doi.org/10.1182/blood-2016-03-643544 (2016).
Wahl, M. C., Will, C. L. & Lührmann, R. The spliceosome: Design principles of a dynamic RNP machine. Cell 136, 701–718. https://doi.org/10.1016/j.cell.2009.02.009 (2009).
Cretu, C. et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol. Cell. 64, 307–319. https://doi.org/10.1016/j.molcel.2016.08.036 (2016).
Bondu, S. et al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci. Transl. Med. 11, 5467. https://doi.org/10.1126/scitranslmed.aav5467 (2019).
Malcovati, L. et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 118, 6239–6246. https://doi.org/10.1182/blood-2011-09-377275 (2011).
Boultwood, J. et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS ONE 3, e1970. https://doi.org/10.1371/journal.pone.0001970 (2008).
Dolatshad, H. et al. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia 30, 2322–2331. https://doi.org/10.1038/leu.2016.149 (2016).
Mupo, A. et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia 31, 720–727. https://doi.org/10.1038/leu.2016.251 (2017).
Clough, C. A. et al. Coordinated mis-splicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood https://doi.org/10.1182/blood.2021012652 (2021).
Kanagal-Shamanna, R. et al. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127, 3552–3565. https://doi.org/10.1002/cncr.33745 (2021).
Hsu, J. et al. Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. Blood 134, 186–198. https://doi.org/10.1182/blood.2018884338 (2019).
Hatta, S. et al. A defined culture method enabling the establishment of ring sideroblasts from induced pluripotent cells of X-linked sideroblastic anemia. Haematologica 103, e188–e191. https://doi.org/10.3324/haematol.2017.179770 (2018).
Saito, K. et al. Generation and molecular characterization of human ring sideroblasts: A key role of ferrous iron in terminal erythroid differentiation and ring sideroblast formation. Mol. Cell. Biol. 39, e00387-e418. https://doi.org/10.1128/MCB.00387-18 (2019).
Kurita, R. et al. Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS ONE 8, e59890. https://doi.org/10.1371/journal.pone.0059890 (2013).
Fujiwara, T. et al. Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU 1. Biochem. Biophys. Res. Commun. 485, 380–387. https://doi.org/10.1016/j.bbrc.2017.02.068 (2017).
Gallagher, P. G., Romana, M., Tse, W. T., Lux, S. E. & Forget, B. G. The human ankyrin-1 gene is selectively transcribed in erythroid cell lines despite the presence of a housekeeping-like promoter. Blood 96, 1136–1143. https://doi.org/10.1182/blood.V96.3.1136 (2000).
Bishop, T. R., Miller, M. W., Beall, J., Zon, L. I. & Dierks, P. Genetic regulation of delta-aminolevulinate dehydratase during erythropoiesis. Nucleic Acids Res. 24, 2511–2518. https://doi.org/10.1093/nar/24.13.2511 (1996).
Aashaq, S., Batool, A. & Andrabi, K. I. TAK1 mediates convergence of cellular signals for death and survival. Apoptosis 24, 3–20. https://doi.org/10.1007/s10495-018-1490-7 (2019).
de Thonel, A. et al. HSP27 controls GATA-1 protein level during erythroid cell differentiation. Blood 116, 85–96. https://doi.org/10.1182/blood-2009-09-241778 (2010).
Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative genomics viewer (IGV): High-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178–192. https://doi.org/10.1093/bib/bbs017 (2013).
Lieu, Y. K. et al. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proc. Natl Acad. Sci. USA 119, 1. https://doi.org/10.1073/pnas.2111703119 (2022).
Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat. Methods 7, 1009–1015. https://doi.org/10.1038/nmeth.1528 (2010).
Mahi, N. A., Najafabadi, M. F., Pilarczyk, M., Kouril, M. & Medvedovic, M. GREIN: An interactive web platform for re-analyzing GEO RNA-seq data. Sci. Rep. 9, 7580. https://doi.org/10.1038/s41598-019-43935-8 (2019).
Pellagatti, A. et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations. Blood 132, 1225–1240. https://doi.org/10.1182/blood-2018-04-843771 (2018).
Ge, S. X., Son, E. W. & Yao, R. iDEP: An integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinform. 19, 534. https://doi.org/10.1186/s12859-018-2486-6 (2018).
Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523. https://doi.org/10.1038/s41467-019-09234-6 (2019).
Pondarre, C. et al. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 109, 3567–3569. https://doi.org/10.1182/blood-2006-04-015768 (2007).
Rouault, T. A. & Maio, N. Biogenesis and functions of mammalian iron-sulfur proteins in the regulation of iron homeostasis and pivotal metabolic pathways. J. Biol. Chem. 292, 12744–12753. https://doi.org/10.1074/jbc.R117.789537 (2017).
Moenner, M., Vosoghi, M., Ryazantsev, S. & Glitz, D. G. Ribonuclease inhibitor protein of human erythrocytes: Characterization, loss of activity in response to oxidative stress, and association with Heinz bodies. Blood Cells Mol. Dis. 24, 149–164. https://doi.org/10.1006/bcmd.1998.0182 (1998).
Chennupati, V. et al. Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 translation. J. Clin. Invest. 128, 15971614. https://doi.org/10.1172/JCI94956 (2018).
Sarangdhar, M. A. & Allam, R. Angiogenin (ANG)-ribonuclease inhibitor (RNH1) system in protein synthesis and disease. Int. J. Mol. Sci. 22, 1287. https://doi.org/10.3390/ijms22031287 (2021).
Maio, N., Kim, K. S., Holmes-Hampton, G., Singh, A. & Rouault, T. A. Dimeric ferrochelatase bridges ABCB7 and ABCB10 homodimers in an architecturally defined molecular complex required for heme biosynthesis. Haematologica 104, 1756–1767. https://doi.org/10.3324/haematol.2018.214320 (2019).
Liu, G. et al. Functional analysis of GLRX5 mutants reveals distinct functionalities of GLRX5 Protein. J. Cell Biochem. 117, 207–217. https://doi.org/10.1002/jcb.25267 (2016).
Yien, Y. Y. et al. TMEM14C is required for erythroid mitochondrial heme metabolism. J. Clin. Invest. 124, 4294–4304. https://doi.org/10.1172/JCI76979 (2014).
Fujiwara, T. et al. Role of transcriptional corepressor ETO2 in erythroid cells. Exp. Hematol. 41, 303–15.e1. https://doi.org/10.1016/j.exphem.2012.10.015 (2013).
Wang, C. et al. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev. 12, 1409–1414. https://doi.org/10.1101/gad.12.10.1409 (1998).
Kesarwani, A. K. et al. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3’ splice sites within RNA secondary structures. Oncogene 36, 1123–1133. https://doi.org/10.1038/onc.2016.279 (2017).
Morgenstern, J. P. & Land, H. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587–3596. https://doi.org/10.1093/nar/18.12.3587 (1990).
Mizuta, S. et al. Evaluation of SF3B1 mutation screening by high-resolution melting analysis and its clinical utility for myelodysplastic syndrome with ring sideroblasts at the point of diagnosis. Lab. Med. 50, 254–262. https://doi.org/10.1093/labmed/lmy070 (2019).
Kim, D., Langmead, B. & Salzberg, S. L. HISAT: A fast spliced aligner with low memory requirements. Nat. Methods 12, 357–360. https://doi.org/10.1038/nmeth.3317 (2015).
Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290–295. https://doi.org/10.1038/nbt.3122 (2015).
Lewis, B. P., Green, R. E. & Brenner, S. E. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc. Natl Acad. Sci. USA 100, 189–192. https://doi.org/10.1073/pnas.0136770100 (2003).
Mufti, G. J. et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93, 1712–1717. https://doi.org/10.3324/haematol.13405 (2008).
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675. https://doi.org/10.1038/nmeth.2089 (2012).
Acknowledgements
The authors thank members of the Department of Hematology, Tohoku University Graduate School of Medicine for their helpful discussions and support, staff of the Biomedical Research Core of Tohoku University Graduate School of Medicine for their technical support, Toshio Kitamura (Tokyo University) for providing PLAT-GP packaging cells, and SBI Pharmaceuticals Co., Ltd. For providing SFC. This study was supported by JSPS KAKENHI Grant No. 18K08314 to T.F.
Author information
Authors and Affiliations
Contributions
T.O., T.F., and H.H. conceived and designed the experiments; T.O., T.F., K.O. (Ono), C.S., and M.N. performed the experiments and analyzed the data; T.F., D.I., H.K., K.O. (Onodera), S.I., N.F., Y.O., H.Y., Y.N., and H.H. contributed reagents, materials, and analytical tools; T.O., T.F., and H.H. wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ochi, T., Fujiwara, T., Ono, K. et al. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. Sci Rep 12, 14562 (2022). https://doi.org/10.1038/s41598-022-18921-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-022-18921-2
- Springer Nature Limited